Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03788512
Other study ID # CoCCA
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 12, 2019
Est. completion date December 2027

Study information

Verified date January 2022
Source Xuanwu Hospital, Beijing
Contact Xin Ma, MD, PhD
Phone 13501390691
Email maxin118@hotmail.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Coexistence of Cerebral and Coronary Atherosclerosis in Acute Ischemic Cerebrovascular Disease Patients Registry (CoCCA) is a single-center observational registry of patients hospitalized for acute ischemic cerebrovascular disease (AICVD) with atherosclerotic changes in both cerebral and coronary arteries. This registry aims to establish quantified risk stratification and prognostic models, as well as suggest effective diagnostic and therapeutic strategies.


Description:

Atherosclerosis has exerted huge global burden as the common pathological process underlying ischemic heart disease and cerebrovascular disease. A substantial portion of acute ischemic cerebrovascular disease (AICVD) patients have both cerebral and coronary atherosclerosis, which is an omen of poor outcomes. But there is large evidence gap in these high-risk patients' prognosis-related factors, limiting the improvement of care quality. Coexistence of Cerebral and Coronary Atherosclerosis in Acute Ischemic Cerebrovascular Disease Patients Registry (CoCCA) is a single-center prospective observational registry of patients hospitalized for AICVD with atherosclerotic changes in both cerebral and coronary arteries. This registry aims to establish quantified risk stratification and prognostic models, as well as suggest effective diagnostic and therapeutic strategies. The clinical, imaging and laboratory information will be collected at the baseline. During an estimated 5-year follow-up, the vessel-related diagnostic or monitoring procedures, treatment, functional status and new vascular events will be recorded by web-based patients' self-reports, investigators' regular telephone visits.


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date December 2027
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: 1. Diagnosed as ischemic stroke or transient ischemic attack (TIA). 2. Less than 30 days after onset of ischemic stroke or TIA symptoms. 3. Extracranial or intracranial cerebral atherosclerosis confirmed by vascular ultrasound or CT angiograpgy or MR angiograpgy or digital substraction angiography. 4. Coronary atherosclerosis confirmed by CT angiograpgy or MR angiograpgy or digital substraction angiography; or with myocardial ischemia symptoms confirmed using electrocardiogram or echocardiography or cardiac MR; or with a history of percutaneous coronary intervention or coronary artery bypass graft. Exclusion Criteria: 1. With malignant tumors or poor organ functions or hematologic diseases, whose estimated life expectancy is less than 5 years. 2. Patients refuse to participate in the research.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
observational only- no intervention
observational only- no intervention

Locations

Country Name City State
China Xuanwu Hospital, Capital Medical University Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Xuanwu Hospital, Beijing

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of Major Adverse Cardiovascular Events cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death), ischemic stroke, myocardial infarction and unstable angina 1 year
Secondary Rate of Major Adverse Cardiovascular Events cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death), ischemic stroke, myocardial infarction and unstable angina 90 days
Secondary Functional Outcome Percentage of patients with modified Rankin Scale (mRS) scores (minimum 0 and maximum 5) 3 to 5, who are considered to be disabled. 90 days
Secondary Rate of Ischemic Stroke fatal and nonfatal ischemic stroke. 1 year
Secondary Rate of Acute Coronary Syndrome fatal and nonfatal myocardial infarction and unstable angina 1 year
Secondary Rate of Cardiovascular Mortality any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death 1 year
Secondary Time to First Major Adverse Cardiovascular Event from the date of enrollment until the date of first documented cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death), ischemic stroke, myocardial infarction or unstable angina, whichever comes first, assessed up to 5 years 5 years
Secondary Time to First Ischemic Stroke from the date of enrollment until the date of first documented ischemic stroke, assessed up to 5 years 5 years
Secondary Rate of Major Adverse Cardiovascular Events cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death), ischemic stroke, myocardial infarction and unstable angina 5 years
Secondary Rate of Ischemic Stroke fatal and nonfatal ischemic stroke 5 years
Secondary Rate of Acute Coronary Syndrome fatal and nonfatal myocardial infarction and unstable angina 5 years
Secondary Rate of Cardiovascular Mortality any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death 5 years